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Epstein-Barr virus (EBV)-associated post-transplant smooth muscle tumours (PTSMT) are rare complications. In our
previous molecular analysis, we have evaluated the expression of regulatory microRNA which are known to be
EBV-related (miR-146a and miR-155) but found no deregulation in PTSMT. In this current analysis, we aimed to
characterize the expression profiles of several hundred microRNA. Tissue samples from PTSMT and uterine
leiomyomas were analysed by quantitative real-time PCR for the expression of 365 mature microRNA. PTSMT and
leiomyomas share a highly similar microRNA profile, e.g. strong expression of miR-143/miR-145 cluster and low
expression of miR-200c. Among EBV-related microRNA (miR-10b, miR-21, miR-29b, miR-34a, miR-127, miR-146a,
miR-155, miR-200b, miR-203 and miR-429) only miR-10b and miR-203 were significantly deregulated. The expression
pattern of microRNA in PTSMT is not associated with EBV infection but reflects the leiomyomatous differentiation of
the tumour cells.
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Epstein-Barr virus (EBV)-associated diseases are often
associated with acquired or congenital immunosuppres-
sion or immunodeficiency, e.g. bone marrow and solid
organ-transplanted patients are at a higher risk. Up to
10% of transplant recipients develop post-transplant
lymphoproliferative disorders (PTLD) while EBV-associated
post-transplant smooth muscle tumours (PTSMT) are rare
complications (<1% of transplant patients) [1,2]. Neoplastic
spindle cells in PTSMT express leiomyogenous marker
proteins such as smooth muscle actin and desmin, and the
majority of tumour cells is positive for EBER. We could
previously show that PTSMT differ from conventional
leiomyosarcomas by their lack of marked atypia, unusual
sites of involvement (>50% in the recipient or donor liver)
and defined EBV association [2].
The molecular pathobiology of this rare neoplastic en-
tity is not fully understood and only few experimental* Correspondence: Hussein.Kais@MH-Hannover.de
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reproduction in any medium, provided the oranalyses have addressed this issue. Ong et al. [3] have
analysed cell cycle factors, cytokines and gene promoter
methylation in PTSMT and found an activated mTOR/
Akt cell cycle pathway by demonstrating phosphorylated
mTOR in tumour cells. In our previous analysis, we have
evaluated the expression of EBV-associated human genes
in PTSMT, including transcription, cell cycle and apoptosis
factors and cytokines/cytokine receptors [2]. We found that
the transcription factor v-myc myelocytomatosis viral on-
cogene homolog (avian) (MYC) is significantly upregulated
in PTSMT. In addition to mRNA, we have analysed micro-
RNAs which are known to be expressed in an EBV-related
fashion (miR-146a and miR-155) but in PTSMT we found
low expression levels and no delimitable deregulation.
MicroRNAs are non-coding RNA molecules of 20–25
nucleotides in length [4,5]. These small RNA molecules
can bind semi-complementarily to the 3′-untranslated re-
gion (3′-UTR) of target mRNAs and repress translation or
target mRNA for degradation. The microRNA genes can
be present as single gene or gene clusters (different
microRNA species are encoded on the same chromosome
segment). Furthermore, microRNA families representLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 MicroRNA with a mean relative expression level
of >1 (p <0.05*; p <0.01**)
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but very similar mature microRNA with no or minor dif-
ferences in their nucleotide sequence.
Aberrant microRNA expression patterns have been
identified in several neoplasms and are known to con-
tribute to the deregulated cell homeostasis in tumour
cells, e.g. leiomyomas [6-17]. In this current analysis, we
aimed to characterize the expression profiles of several
hundred microRNA in PTSMT, in particular regarding




All available PTSMT samples from our tissue archive were
evaluated; these PTSMT cases have been characterized
earlier [2]. Five EBV+ PTSMT samples from four patients,
including two tumours from one patient (#4) were analysed
(Additional file 1: Table S1). Controls: seven EBV- benign
uterine leiomyomas. Formalin-fixed and paraffin-embedded
(FFPE) samples were retrieved from the archives of the
Institute of Pathology (Hannover Medical School/MHH,
Hannover, Germany). The retrospective analysis of the
samples has been approved by the local ethics committee
of the Hannover Medical School (MHH).
Laser microdissection of the PTSMT compartment and
gene expression analysis
Tissue from FFPE blocks with >90% tumour cells were
cut and processed for further PCR analysis. In blocks with
<90% aberrant cells, the PTSMT compartments were
laser microdissected using a SmartCutPlus-System (MMI,
Glattbrugg, Switzerland), as previously described [2].
A set of 365 mature microRNA and corresponding en-
dogenous controls were analysed by quantitative real-time
PCR (Pool A, Applied Biosystems, Carlsbad, CA, USA). In
brief, cells were digested in proteinase K and RNA was
extracted with phenol/chloroform [2,18,19]. Synthesis of
cDNA from microRNA, subsequent pre-amplification of
cDNA and real-time quantitative PCR with a 7900HT Fast
Real-Time PCR system were performed according to the
manufacturers’ instructions (Applied Biosystems).
Data analyses
The sample- and detector-specific evaluation of amplifica-
tion curves was accomplished with the software RQ
Manager 1.2 (Applied Biosystems). CT values established
in this manner were converted into ΔCT values and into
2-ΔCT values (normalized to mean of endogenous control
genes). Statistical analysis was performed with Prism 5.0
(GraphPad Software, San Diego, California, USA) by ap-
plying the Mann–Whitney test for two-group comparison.
P values < 0.05 were considered as statistically significant.Cluster analysis was performed with the Qlucore Omics
Explorer 2.2 (Qlucore AB, Lund, Sweden).
For target prediction, an open access bioinformatics
platform was used (http://www.targetscan.org/).
Results
Similar microRNA expression profile in PTSMT and
leiomyomas
Cluster analysis of the expression profile of 365 micro-
RNA revealed that PTSMTand leiomyomas share a highly
similar profile (Additional file 2: Table S2); cluster analysis
could not discriminate between the two tumours.
In PTSMT, only 15/365 microRNA and in leiomyomas
23/365 microRNA showed a mean relative expression level
of >1 (Table 1). The five microRNA with the highest
expression levels in PTSMT and leiomyomas were the
miR-143/miR-145 cluster (both genes are encoded on
chromosome region 5q32), miR-24 (two genes on segments
9q22.32 and 19p13.13 encode for the mature miR-24 mol-
ecule), let-7b (22q13.31) and miR-21 (17q23.1). In general,
most microRNA were expressed at low levels (<1 relative
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the leiomyomatous phenotype-associated miR-150 (mean
relative level of 0.38 in leiomyomas versus 0.37 in PTSMT),
miR-221 (0.09 versus 0.01) andmiR-200c (0.00 versus 0.01).
In PTSMT, 59/365 microRNA were significantly de-
regulated compared with leiomyomas: a set of 51/59
microRNA were down-regulated and 8/59 were up-
regulated (Figure 1). However, most of these signifi-
cances in down-regulated microRNA are a result of very
low expression in PTSMT versus low expression in
leiomyomas (<1 mean relative expression level), e.g.
let-7c (0.22 in leiomyomas versus 0.01 in PTSMT) and
miR-221 (0.09 versus 0.01). Furthermore, significantly
up-regulated microRNA in PTSMT were a result of very
low expression levels in leiomyomas rather than bio-
logically relevant increased expression in PTSMT. In
these 8/59 microRNA, the highest relative expression levels
were less than 0.5 (miR-181a, miR-34c, miR-142-3p;
Figure 1) or even less than 0.05 in PTSMTand leiomyomas
(miR-138, miR-181c, miR-190, miR-330-3p/-5p, miR-504).
Minor association of microRNA expression with EBV
infection in PTSMT
The following microRNA are known to be related to EBV
infection in solid tumours and haematopoietic malignan-
cies (Additional file 3: Table S3) [20-33]: miR-10b, miR-21,
miR-29b, miR-34a, miR-127, miR-146a, miR-155, miR-Figure 1 Representative selection of significantly (p <0.01) de-regulated
microRNA. D-F) Up-regulated microRNA in PTSMT show relative expression le200b, miR-203 and miR-429. Only two of these microRNA
were significantly down-regulated in EBV+ PTSMT: miR-
10b (mean relative expression of 0.45 in leiomyomas versus
0.01 in PTSMT) and miR-203 (0.01 versus 0.00). Further-
more, in leiomyomas, the level of miR-21 was higher than
in PTSMT but the difference did not reach statistical
significance (5.40 versus 1.34; p = 0.0876). As could be
expected from our previous experiments, miR-146a and
miR-155 were not deregulated while the miR-146a-homo-
log miR-146b was significantly down-regulated in PTSMT
(mean 0.23 versus 0.73 in leiomyomas; p = 0.0101). Other
EBV-related microRNA (miR-29b, miR-34a, miR-200b and
miR-429) were expressed at similarly low levels in both
leiomyomas and PTSMT (not significantly deregulated).
Discussion
No EBV-related microRNA deregulation in
EBV+/LMP1- PTSMT
In our first molecular analysis of PTSMT, we analysed
the expression of miR-146a and miR-155 because these
microRNA are known to be involved in the pathobiology
of EBV infection of B cells [2,34,35]. In our current ana-
lysis, we could confirm our previous results and found
no significant deregulation of these two microRNA using
a microarray technique. Furthermore, it is remarkable
that several EBV-related microRNA, other than miR-
146a and miR-155, are not deregulated in PTSMT. InmicroRNA expression in PTSMT. A-C) Examples of down-regulated
vels below 0.5.
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miR-127, which are increased in EBV+ nasopharyngeal
carcinoma and high grade B cell lymphomas/Burkitt
lymphomas [20-33], were expressed at low or very low
levels in PTSMT. In non-PTSMT EBV+ carcinomas and
lymphomas miR-200b, miR-203 and miR-429 are gener-
ally expressed at low levels [20-33]. In PTSMT, but also
in EBV- leiomyomas, these microRNAs were also
expressed at low levels, indicating no specific EBV-
related decreased expression in smooth muscle tumours.
It has to be taken into account that different cell and
tumour types can react in different manners to EBV
infection. Furthermore, depending on the latency type,
EBV induces expression of different virus proteins,
which interfere in the host cell cycle. Latent membrane
protein 1 (LMP1) is one of these EBV proteins and it
has been shown that LMP1 alone can induce altered
microRNA expression in nasopharyngeal carcinomas
and lymphomas [20-33]. We and others have found
previously that EBV+ PTSMT express EBNA2 and
EBNA3 while LMP1 expression is weak or not detect-
able [2,3,36,37]. Thus, despite EBV infection in PTSMT,
our finding of no major changes in the microRNA ex-




MicroRNA expression analyses in uterine leiomyomas
and leiomyosarcomas were introduced only a few years
ago (Additional file 4: Table S4) [6-17]. The majority of
studies have evaluated patient-derived leiomyomas as a
model disease of neoplastic smooth muscle proliferation.
Among different studies and different analytical methods,
microRNA expression patterns of patient-derived tumour
samples showed a set of microRNA which are recurrently
deregulated in comparison to normal uterus wall cells.
Similar to PTSMT, decreased expression of miR-150,
miR-200c and miR-221 and increased expression of miR-
21 and let-7 family members have become particularly evi-
dent in leiomyomas [6-17]. It has been demonstrated that
mesenchymal cells which differentiate into smooth muscle
cells in vitro change their microRNA expression patterns,
e.g. down-regulation of 13q31.3-clustered miR-17/miR-
18a/miR-20a and up-regulation of miR-181a/miR-181c
paralogs [16]. Furthermore, in smooth muscle cells, it has
been shown that the 5q32-encoded miR-143/miR-145
cluster is co-expressed [38,39]. Both microRNA target a
network of factors to promote vascular smooth muscle
cell differentiation and repress proliferation [38,39]. We
could previously demonstrate high expression of miR-143
and even higher expression of miR-145 in pulmonary
vessel wall cells [40]. A similar expression pattern of high
miR-143 and higher miR-145 could also be found inPTSMT but also in leiomyomas. Because PTSMT can be
found next to vessels (e.g. manifestation in cerebral sinus),
it is thought that the aberrant founder cells might be
derived from a vessel wall [2,41]. However, due to very
similar miR-143/miR-145 expression patterns in PTSMT,
uterus wall-derived leiomyomas and pulmonary vessels,
the high expression of these two microRNA does not
prove a vessel wall origin of PTSMT but reflects the
smooth muscle differentiation.
In PTSMT and leiomyomas, many microRNA are
expressed at low or very low levels, which makes it likely
that protein translation of potential target mRNA types
is not inhibited. The problem for target prediction, but
simultaneously the hallmark of microRNA/mRNA bio-
logy, is the characteristic semi-complementary binding
of the seven nucleotides at the 3′-end of the mature
microRNA (so-called seed sequence) to corresponding
mRNA-nucleotides of the 5′-UTR [4,5]. This semi-
complementary binding is sufficient to induce a biological
effect, the inhibition of mRNA/protein translation. As a
result, one microRNA can bind to several 5′-UTR-mRNA
and vice versa one 5′-UTR-mRNA can be targeted by
several microRNA. In our previous analysis, we have
evaluated the expression of several mRNA transcripts in
PTSMT and leiomyomas, including MYC, vascular endo-
thelial growth factor A (VEGFA), nuclear factor of kappa
light polypeptide gene enhancer in B-cells 1 (NFKB1),
tumour protein p53 (TP53), transforming growth factor,
beta receptor II (TGFBR2) and transforming growth fac-
tor, beta 1 (TGFB1) [2].
Among several EBV-associated human factors, we
found only MYC to be significantly increased in PTSMT
[2]. The mRNA of this transcription factor can be regu-
lated by miR-150, miR-143 and miR-145 [42,43] but no
PTSMT-specific inverse correlation was found.
VEGFA can be negatively regulated by miR-200c and
other microRNA. In leiomyomatous cell lines, miR-200c
interaction with VEGFA has been shown [7] and accord-
ingly, in leiomyomas as well as in PTSMT, very low levels
of miR-200c correlate with increased levels of VEGFA [2].
In many different tumour types, miR-21 is aberrantly
expressed, because this microRNA can target several
signal networks, either directly by binding to different
types of mRNA from similar signal cascades or indirectly
via deregulation of factors down/up-stream to the fac-
tors directly suppressed by miR-21 [44,45]. In particular,
miR-21 is a negative regulator of TP53 signalling and
simultaneously a promoter of NFKB1 signalling [44,45].
Increased expression of miR-21 has been previously
demonstrated in leiomyomas [6,10,15,16] which we
could confirm in our analysis. In smooth muscle cells,
miR-21 is involved in regulation of apoptosis and
TGFBR2/TGFB1 signalling [6,10,13]. TGFBR2-3′UTR
has an miR-21 binding site and can therefore directly be
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studies also suggested an indirect regulatory interaction
between miR-21 and TGFB1; of note, TGFB1 is not a
direct target of miR-21 [10]. Furthermore, inhibition of
miR-21 expression in smooth muscle cells indirectly
increases caspase 3 and caspase 7 activity in vitro; both
caspases have no miR-21 binding site [6,13]. The miR-21
expression was lower in PTSMT than leiomyomas but
the difference was not significant. In addition, in our pre-
vious analysis we found no differences in the expression of
miR-21-related NFKB1, TP53, TGFBR2 or TGFB1 between
PTSMTand leiomyomas [2]. Therefore, our in situ-derived
results do not reveal a PTSMT-specific deregulated miR-21
signal cascade, but an expression pattern related to smooth
muscle phenotype.
Members of the let-7 family are increased in leiomyomas
[15] and smooth muscle cell lines, e.g. let-7b [13,16]. We
found that in PTSMT and leiomyomas, the strongest
expressed let-7 paralog was let-7b. In leiomyomas and
leiomyosarcomas, let-7c shows an inverse correlation with
its target mRNA high mobility group AT-hook 2 (HMGA2)
[11,17]. Both genes, let-7c and HMGA2, are expressed in
association with size of leiomyomas [11], while in PTSMT,
irrespective of the size, let-7c was almost absent.
In summary, in addition to leiomyomas and leiomyo-
sarcomas, PTSMT is the third smooth muscle tumour type
in which the microRNA expression profile could be evalu-
ated. The expression pattern of microRNA in PTSMT is
not associated with EBV infection (presumably due to lack
of strong LMP1 expression) but reflects the leiomyomatous
differentiation of the tumour cells.Additional files
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